Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 5/20 | 0.38 |
| ▸ | NR1I3 | Q14994 | 5/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 6/20 | 0.37 |
| ▸ | MMP3 | P08254 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19632861 | 0.86 | AGPAT2 (0.39) | NAMPT | |
| SCHEMBL19614928 | 0.86 | NAMPT (0.42) | DRD2NAMPTNR1I3PRMT5WDR77 | |
| SCHEMBL19633055 | 0.85 | NAMPT (0.38) | NAMPTHDAC1 | |
| SCHEMBL30944502 | 0.85 | NAMPT (0.42) | DRD2NAMPTNR1I3 | |
| SCHEMBL30944532 | 0.85 | NAMPT (0.42) | DRD2NAMPTNR1I3 | |
| SCHEMBL30944533 | 0.80 | CYP17A1 (0.41) | DRD2NAMPTHDAC1 | |
| SCHEMBL19636843 | 0.80 | GRM4 (0.35) | DRD2NAMPTNR1I3 | |
| SCHEMBL19633223 | 0.79 | NAMPT (0.43) | DRD2NAMPTHDAC1 | |
| SCHEMBL19633096 | 0.78 | FGFR1 (0.37) | NAMPT | |
| SCHEMBL23629625 | 0.74 | NAMPT (0.50) | DRD2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458069-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3458069-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | DRD2 53/4885NAMPT 3033/4885NR1I3 1354/4885 |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | DRD2 53/4885NAMPT 3033/4885NR1I3 1354/4885 |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | CD79B, CLTB, FCGR3B | DRD2 53/4885NAMPT 3033/4885NR1I3 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.